Anti-PD-L1/CD274 Rabbit Polyclonal Antibody for WB, IF-P, IHC-P, ELISA - Q9NZQ7

Core Product Specifications and Parameters

Biological Background: PD-L1/CD274 Function and Localization

• PD-L1 (Programmed cell death 1 ligand 1), also known as B7-H1, is encoded by the CD274 gene; it is a member of the B7 family of immunoglobulin superfamily ligands.
• As a ligand for the inhibitory receptor PD-1, PD-L1 plays a critical role in induction and maintenance of immune tolerance to self, modulating the activation threshold of T-cells and limiting T-cell effector responses. Related references: PMID:11015443, PMID:28813410, PMID:28813417
• PD-L1 may also costimulate T-cell subsets that predominantly produce interleukin-10 (IL-10) through an as yet unidentified activating receptor. Related references: PMID:10581077
• In response to hypoxia, PD-L1 translocates to the nucleus via its interaction with phosphorylated STAT3 and acts as a transcription coactivator to promote GSDMC transcription, leading to pyroptosis. Related references: PMID:32929201
• PD-L1 is primarily a transmembrane protein located at the cell membrane, early endosome membrane, and recycling endosome membrane; it can also be secreted and, upon specific stimuli, enter the nucleus.
• Widely expressed in tissues such as heart, skeletal muscle, placenta, and lung, and on activated immune cells including T-cells, B-cells, dendritic cells, and monocytes. Tumor cells often upregulate PD-L1 to exploit the PD-1 inhibitory pathway, attenuating anti-tumor immunity and promoting immune escape, making it a major target for cancer immunotherapy.
• PD-L1 is a glycoprotein containing disulfide bonds and potential ubiquitin-like conjugation sites, which may influence its stability and receptor interactions.

Experimental Guidance and Technical Tips

• The immunogen corresponds to the extracellular domain (residues 190–290) of human PD-L1, which contains the IgV-like region critical for PD-1 interaction; this design supports detection of both full-length and soluble forms.
• In Western blotting, a primary band near 33 kDa is predicted, but glycosylation may shift the apparent molecular weight to 40–50 kDa; consider using positive controls from placenta, lung, or activated immune cells.
• For immunohistochemistry (IHC-P) and immunofluorescence (IF-P), standard antigen retrieval techniques and optimization of blocking conditions are recommended; the antibody's cross-reactivity with mouse and rat PD-L1 allows for multispecies studies.
• ELISA applications can be developed using the antibody as either capture or detection reagent after appropriate validation.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers and research institutions with a streamlined, single-vendor solution for IVD raw material procurement. For PD-L1/CD274-focused immuno-oncology assay development, we supply validated polyclonal and monoclonal antibodies, recombinant proteins, and ancillary reagents—backed by our expertise in sourcing rare targets. Whether you need antibody pairs, bulk antigens, or customized support, CamelBio bridges your concept to clinical application.